Bile Duct Cancer
TOPAZ-1's 3-year follow-up is the longest survival follow-up for a global, randomized phase III trial in this setting.
Dr. William Jarnagin discusses his recent study on characterizing the heterogeneity of intrahepatic cholangiocarcinoma.
This approval marks the first tumor-agnostic approval of a HER2-directed therapy.
Dr. Abou-Alfa describes the promising outcomes of infigratinib and delves into further research on FGFR alterations in CCA.
Patients who underwent targeted therapy for IDH1/2 alterations or FGFR2 fusions showed a 100% concordance rate.
The developed nomogram was found to provide significant diagnostic accuracy with an area under the curve level of 0.882.
Meta-analysis data has shown that HAIP combined with systemic chemotherapy can provide a pooled 3-year OS rate of 39.5%.
Dr. Amit Mahipal discusses liquid biopsy for advanced cholangiocarcinoma and how it compares to tissue-based testing.
Dr. Milind Javle discusses tinengotinib monotherapy in patients with metastatic cholangiocarcinoma at ASCO GI 2024.
The most common first-line therapies were gemcitabine and cisplatin.
The FDA approved futibatinib in 2022 for previously treated patients with advanced CCA and FGFR2 fusions or rearrangements.
New research sheds light on the prognostic value of mutations—including FGFR2 and IDH1—in patients with resectable CCA.
Advertisement
Expert Interviews on GI Oncology
Advertisement
